Retinoic acid receptor gamma (RARG) (RARG)

Retinoic acid receptor gamma (RARG) is a nuclear receptor and ligand-dependent transcription factor that plays a fundamental role in mediating the biological effects of vitamin A derivatives. It is the predominant retinoic acid receptor isoform in human skin, where it is essential for regulating the growth, differentiation, and maintenance of the epidermis. When activated by natural or synthetic ligands, RARG heterodimerizes with the retinoid X receptor (RXR) to bind specific DNA sequences, thereby modulating the expression of genes critical for cellular homeostasis and inflammatory signaling. In clinical practice, RARG is a primary target for topical retinoids like adapalene, which are used to treat acne vulgaris by normalizing keratinocyte turnover and preventing the formation of microcomedones. Beyond dermatology, RARG is involved in skeletal development and has been identified as a potential target or factor in various malignancies and rare ossification disorders.

Other names

NR1B3RAR-gammaRARCRetinoic acid receptor gamma-1Retinoic acid receptor gamma-2

Retinoic acid receptor gamma (RARG) acts as a ligand-activated transcription factor. Upon binding an agonist, such as retinoic acid or synthetic retinoids like adapalene, it undergoes a conformational change that facilitates heterodimerization with a retinoid X receptor (RXR). This complex binds to retinoic acid response elements (RAREs) in the DNA, leading to the recruitment of coactivators and the subsequent transcription of genes that regulate cell differentiation, proliferation, and apoptosis. In the skin, this results in the normalization of keratinocyte differentiation, reduced comedone formation, and anti-inflammatory effects through the inhibition of pathways such as AP-1 and toll-like receptors.